Oxidative stress (OS)-induced neuronal damage and neuroinflammation form a vicious cycle that promotes the progression of Parkinson's disease (PD). Herein, a therapeutic strategy exploiting the tannic acid (TA)-iron (Fe) complex-based nanoparticles (BSA/Fe-TA NPs) that simultaneously relieves brain OS and neuroinflammation is developed for PD therapy. BSA/Fe-TA NPs possess atomically dispersed iron catalytic active sites and display multienzyme-like activities, which can efficiently scavenge reactive oxygen/nitrogen species (RONS). Moreover, they are able to penetrate the blood-brain barrier (BBB) and accumulate in neurons and microglia, thereby mitigating OS in the brain microenvironment via efficient intracellular and extracellular RONS elimination and regulating the polarization of microglia into the anti-inflammatory M2-phenotype to relieve neuroinflammation. After systemic administration, BSA/Fe-TA NPs significantly ameliorate PD progression in a mouse model without inducing adverse effects. Moreover, BSA/Fe-TA NPs can be degraded with the assistance of the clinical iron-chelating ligand deferoxamine, thus accelerating their elimination in vivo.
Tannic Acid-Iron Complex-Based Nanozyme Ameliorates Parkinson's Disease via Relieving Oxidative Stress and Neuroinflammation.
Wenya He,Meng Liu,Tong-qing Zhang,Yajing Sun,Yaping Wang,Hongyang Wu,Meng Zheng,B. Shi,Yan Zou
Published 2025 in ACS Nano
ABSTRACT
PUBLICATION RECORD
- Publication year
2025
- Venue
ACS Nano
- Publication date
2025-09-11
- Fields of study
Medicine, Chemistry
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-68 of 68 references · Page 1 of 1
CITED BY
Showing 1-9 of 9 citing papers · Page 1 of 1